Poland· PL-100315835
Tandemact
A glimepiride and pioglitazone product containing pioglitazonum + glimepiridum, registered in Poland by CHEPLAPHARM Arzneimittel GmbH. The same ATC class is registered in 10 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Glimepiride and pioglitazone is registered in 10 of 19 countries.
Countries holding a registration under ATC A10BD06 (glimepiride and pioglitazone), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Glimepiride and pioglitazone · ATC A10BD06
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Pioglitazonum + Glimepiridum
- Manufacturer
- CHEPLAPHARM Arzneimittel GmbH
- Country
- Poland (PL)
- ATC code
- A10BD06
- ATC class
- Glimepiride and pioglitazone
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
1 interaction on record for glimepiride and pioglitazone.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Glimepiride and pioglitazone · interactions on record
1 record
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Glimepiride and pioglitazone in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesDuetactTakeda Pharmaceuticals America, Inc.
- CzechiaTANDEMACTCHEPLAPHARM Arzneimittel GmbH, Greifswald
- FinlandTandemactCheplapharm Arzneimittel GmbH
- IcelandTandemactCHEPLAPHARM Arzneimittel GmbH
- NetherlandsTandemact 30 mg/2 mg, tablettenCHEPLAPHARM Arzneimittel GmbH
- SwedenTandemact 30 mg/2 mg TablettCheplapharm Arzneimittel GmbH
- SpainTANDEMACT 30 mg/2 mg COMPRIMIDOSCheplapharm Arzneimittel Gmbh
- IrelandTandemactCHEPLAPHARM Arzneimittel GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tandemact
- Liechtenstein · Tandemact
- Norway · Tandemact
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/10275af8-a06e-46e4-9d9c-16407edee214 GET /v1/drugs/10275af8-a06e-46e4-9d9c-16407edee214?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki",
"source": "urpl",
"strength": "30 mg + 4 mg",
"packaging": "Rp ¦ Skasowane ¦ EU/1/06/366/009 ¦ 91373\n90 tabl.\nRp ¦ Skasowane ¦ EU/1/06/366/010 ¦ 91374\n98 tabl.\nRp ¦ EU/1/06/366/006 ¦ 91375\n28 tabl.\nRp ¦ Skasowane ¦ EU/1/06/366/007 ¦ 91376\n30 tabl.\nRp ¦ Skasowane ¦ EU/1/06/366/008 ¦ 91377\n50 tabl.\nRp ¦ Skasowane ¦ EU/1/06/366/005 ¦ 91378\n14 tabl.",
"substance": "Pioglitazonum 30 mg + Glimepiridum 4 mg",
"common_name": "Pioglitazonum + Glimepiridum",
"pl_product_id": "100315835",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about glimepiride and pioglitazone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.